Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $77.35 | Total: $386.75 |
| 1 | 10 | $65.52 | Total: $655.20 |
| 1 | 25 | $55.51 | Total: $1,387.75 |
| 1 | 50 | $47.32 | Total: $2,366.00 |
| 1 | 100 | $40.95 | Total: $4,095.00 |
Overview
BRD7-IN-1, a modified derivative of BI7273 (BRD79 inhibitor), forms PROTAC VZ185 via linkage to a VHL ligand, demonstrating potent activity against BRD79 with DC50 values of 4.5 and 1.8 nM, respectively [1].
Chemical Properties
| Molecular Formula | C22H28Cl2N4O3 |
| Molecular Weight | 467.39 |
| CAS Numbers | 2448414-48-8 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | Cl.Cl.COc1cc(cc(OC)c1CN1CCNCC1)-c1cn(C)c(=O)c2cnccc12 |
Storage and Handling
0C Short Term, -20C Long Term
References
Zoppi V, et al. Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras [PROTACs] Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau [VHL] Based Dual Degrader Probe of BRD9 and BRD7. J Med Chem. 2019 Jan 24;62[2] 699-726.